1. Home
  2. NTLA vs SBGI Comparison

NTLA vs SBGI Comparison

Compare NTLA & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • SBGI
  • Stock Information
  • Founded
  • NTLA 2014
  • SBGI 1986
  • Country
  • NTLA United States
  • SBGI United States
  • Employees
  • NTLA N/A
  • SBGI N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • SBGI Broadcasting
  • Sector
  • NTLA Health Care
  • SBGI Industrials
  • Exchange
  • NTLA Nasdaq
  • SBGI Nasdaq
  • Market Cap
  • NTLA 1.2B
  • SBGI 970.9M
  • IPO Year
  • NTLA 2016
  • SBGI 1995
  • Fundamental
  • Price
  • NTLA $16.11
  • SBGI $14.37
  • Analyst Decision
  • NTLA Buy
  • SBGI Buy
  • Analyst Count
  • NTLA 20
  • SBGI 6
  • Target Price
  • NTLA $32.30
  • SBGI $20.08
  • AVG Volume (30 Days)
  • NTLA 4.8M
  • SBGI 420.2K
  • Earning Date
  • NTLA 11-06-2025
  • SBGI 11-05-2025
  • Dividend Yield
  • NTLA N/A
  • SBGI 6.95%
  • EPS Growth
  • NTLA N/A
  • SBGI N/A
  • EPS
  • NTLA N/A
  • SBGI 0.74
  • Revenue
  • NTLA $52,857,000.00
  • SBGI $3,481,000,000.00
  • Revenue This Year
  • NTLA $8.90
  • SBGI N/A
  • Revenue Next Year
  • NTLA N/A
  • SBGI $9.50
  • P/E Ratio
  • NTLA N/A
  • SBGI $19.42
  • Revenue Growth
  • NTLA 14.99
  • SBGI 8.11
  • 52 Week Low
  • NTLA $5.90
  • SBGI $11.89
  • 52 Week High
  • NTLA $23.76
  • SBGI $18.46
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 81.73
  • SBGI 54.96
  • Support Level
  • NTLA $10.89
  • SBGI $13.81
  • Resistance Level
  • NTLA $12.03
  • SBGI $14.66
  • Average True Range (ATR)
  • NTLA 0.93
  • SBGI 0.41
  • MACD
  • NTLA 0.34
  • SBGI 0.04
  • Stochastic Oscillator
  • NTLA 95.09
  • SBGI 79.93

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

Share on Social Networks: